• News & Events
  • Contact
  • Home
  • Company
    • History and Mission
    • Team
    • Careers
  • Research
    • Technology
    • Products
  • Clinical trials
  • For patients
  • Partnering
  • News & Events
  • Contact
COR-101 approved for first clinical study

COR-101 approved for first clinical study

by wohlenberg@vierviertel.com | Mar 16, 2021 | 2021, News

CORAT Therapeutics GmbH obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101. The study (ClinicalTrials.gov ID: NCT04674566) is a randomized, double-blind, placebo-controlled, parallel-group,...
Second financing round secured for the development of COR-101

Second financing round secured for the development of COR-101

by wohlenberg@vierviertel.com | Jan 12, 2021 | 2021, News

A second financing round was closed with NBank Capital, the investment company of NBank. Additional investors came from the private sector in Braunschweig. CORAT Therapeutics is in close coordination with the regulatory authorities and expects the green light for the...
Next Entries »

Recent Posts

  • € 38.7 Mio. German government funding for the clinical development of a Corona medication
  • CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE
  • CORAT antibody COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants, including the fast proliferating “delta” variant
  • CORAT Therapeutics secures additional funding for Phase II clinical evaluation of its COVID-19 treatment
  • TV report on COR-101

Recent Comments

No comments to show.

Contact

Contact Us

Contact

CORAT Therapeutics GmbH
Inhoffenstr. 7
38124 Braunschweig
Germany

Phone +49 1522 4047488
Write an e-mail

Commercial Registry

HRB 208500
Registergericht Braunschweig

V.i.S.d.P.: Dr. Andreas Herrmann

Pages

Home
Company
History and Mission
Careers
Team
Research
Clinical trails
Partnering
News & Events

Social

Twitter

Legal

Imprint
Privacy Statement
Cookie Policy

© Copyright 2021 – CORAT Therapeutics GmbH